Phase II evaluation of E7389 (NSC-707389) [eribulin] in patients with metastatic or recurrent squamous cell carcinoma of the head and neck

Trial Profile

Phase II evaluation of E7389 (NSC-707389) [eribulin] in patients with metastatic or recurrent squamous cell carcinoma of the head and neck

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2015

At a glance

  • Drugs Eribulin (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Dec 2007 The expected completion date for this trial is now 1 Dec 2007.
    • 20 Dec 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top